TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$17.1

Market cap

$19.37B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.44

Enterprise value

$36.32B

Highlights
Teva Pharmaceutical Industries's EPS has surged by 71% YoY and by 12% QoQ
TEVA's net income has surged by 71% year-on-year and by 12% since the previous quarter
TEVA's quick ratio is down by 13% from the previous quarter and by 13% YoY
Teva Pharmaceutical Industries's equity has decreased by 7% YoY and by 3% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: NVS PFE MRK AZN

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.13B
Market cap
$19.37B
Enterprise value
$36.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
1.2
EV/EBIT
70.51
EV/EBITDA
22.2
EV/Sales
2.27
Earnings
Revenue
$16B
EBIT
$515M
EBITDA
$1.64B
Free cash flow
$878M
Per share
EPS
-$0.44
Free cash flow per share
$0.78
Book value per share
$6.49
Revenue per share
$14.25
TBVPS
$18.44
Balance sheet
Total assets
$42.77B
Total liabilities
$35.23B
Debt
$19.94B
Equity
$7.28B
Working capital
-$1.5B
Liquidity
Debt to equity
2.74
Current ratio
0.89
Quick ratio
0.47
Net debt/EBITDA
10.36
Margins
EBITDA margin
10.2%
Gross margin
49%
Net margin
-3.1%
Operating margin
1.3%
Efficiency
Return on assets
-1.2%
Return on equity
-6.9%
Return on invested capital
2%
Return on capital employed
1.8%
Return on sales
3.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
1.79%
1 week
1.73%
1 month
5.23%
1 year
100.7%
YTD
63.79%
QTD
5.23%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16B
Gross profit
$7.83B
Operating income
$215M
Net income
-$493M
Gross margin
49%
Net margin
-3.1%
TEVA's operating income has soared by 114% YoY but it has plunged by 50% from the previous quarter
The operating margin has soared by 113% YoY but it has shrunk by 52% QoQ
The net margin has surged by 73% year-on-year and by 11% since the previous quarter
TEVA's net income has surged by 71% year-on-year and by 12% since the previous quarter

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
2.63
P/S
1.2
EV/EBIT
70.51
EV/EBITDA
22.2
EV/Sales
2.27
Teva Pharmaceutical Industries's EPS has surged by 71% YoY and by 12% QoQ
TEVA's price to book (P/B) is 135% higher than its 5-year quarterly average of 1.1 and 62% higher than its last 4 quarters average of 1.6
Teva Pharmaceutical Industries's equity has decreased by 7% YoY and by 3% QoQ
The P/S is 69% above the 5-year quarterly average of 0.7 and 48% above the last 4 quarters average of 0.8
TEVA's revenue is up by 7% year-on-year

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
The company's return on invested capital has surged by 140% YoY and by 11% QoQ
Teva Pharmaceutical Industries's return on sales has surged by 134% YoY and by 3.2% QoQ
Teva Pharmaceutical Industries's return on assets has surged by 69% YoY and by 8% QoQ
TEVA's ROE has soared by 66% YoY and by 9% from the previous quarter

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 21% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has decreased by 19% YoY and by 13% QoQ
TEVA's quick ratio is down by 13% from the previous quarter and by 13% YoY
The debt is 174% greater than the equity
Teva Pharmaceutical Industries's equity has decreased by 7% YoY and by 3% QoQ
The debt has declined by 5% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.